JOSHUA KATZ: Open Payments
NPI 1689391872 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,128 in 143 payments from 23 companies in 2025. Trend: 2023 $306 · 2024 $3,900 · 2025 $4,128
Food & beverage: $4,117Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $822 |
| Janssen Biotech, Inc. | 19 | $809 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $330 |
| Phathom Pharmaceuticals, Inc. | 4 | $305 |
| QOL Medical, LLC | 15 | $263 |
| Madrigal Pharmaceuticals | 8 | $257 |
| Novo Nordisk Inc | 4 | $211 |
| Lilly USA, LLC | 5 | $209 |
| Ipsen Biopharmaceuticals, Inc | 5 | $188 |
| GENZYME CORPORATION | 6 | $121 |
Products named: TREMFYA, RINVOQ, VOQUEZNA, Sucraid, REZDIFFRA, ENTYVIO, DUPIXENT, Wegovy.
Industry payments across CO — which companies pay providers there.
